Kodiak Sciences is a brand that is dedicated to developing innovative products and platforms to prevent and treat the leading causes of blindness. Their main focus areas are Diabetic Eye Disease, Retinal Vein Occlusion, and Wet Age Related Macular Degeneration. Kodiak Sciences has a robust pipeline of next-generation retinal medicines that are built on their Antibody Biopolymer Conjugate (ABC) Platform.

This platform allows for the combination of multiple modalities, such as proteins and small molecules, in a single therapeutic. The ABC Platform is designed for durability, enabling the medicines to last longer and extend their therapeutic benefit. It utilizes an engineered bioinspired polymer that creates a water force field around the protein therapeutic, preventing non-specific interactions and providing greater on-target potency.

Furthermore, the ABC Platform allows for the release of hundreds of small molecules over time, enabling the treatment of complex diseases. Kodiak Sciences is pushing the boundaries of ophthalmology and striving to make a difference in the lives of those affected by blindness